Approval of First Gene Therapy for Rare Metabolic Disorder

Introducción

The FDA recently granted accelerated approval for pariglasgene brecaparvovec (Genglycos), marking a significant advancement in the treatment of glycogen storage disease type Ia (GSDIa), a rare inherited metabolic disorder. This condition necessitates regular intake of cornstarch to avert severe or life-threatening hypoglycemia.

Individuals diagnosed with GSDIa experience a deficiency in the enzyme glucose-6-phosphatase (G6PC), which is crucial for converting stored glycogen into glucose, resulting in dangerous fluctuations in blood sugar levels. Therefore, affected individuals must consume special formulations of cornstarch every few hours.

Mecanismo de Acción

This gene therapy utilizes an adeno-associated virus vector to introduce a functional G6PC gene to the liver, directly addressing the underlying cause of the disease. Notably, this treatment is indicated for individuals aged 8 years and older and must be accompanied by nutritional management to help minimize cornstarch consumption.

Approximately 1,500 to 2,500 individuals in the United States are estimated to be living with GSDIa, also referred to as von Gierke disease.

Impacto de la Aprobación

Dr. David Weinstein, a prominent specialist in this rare disease, emphasized the importance of this approval, stating it represents a major breakthrough for the GSDIa community. The rigorous daily management required for GSDIa patients often includes a demanding regimen of raw cornstarch and strict adherence to dietary guidelines, making life extremely challenging for both patients and their families.

Even with meticulous adherence, any missed intake of cornstarch can jeopardize the patient’s safety, leading to severe hypoglycemia, seizures, or even fatal outcomes.

Resultados de los Ensayos Clínicos

Phase III clinical trial results demonstrated that pariglasgene brecaparvovec, when used alongside nutritional management, resulted in a 41.1% reduction in cornstarch intake at 48 weeks. In comparison, the placebo group only experienced a 10.2% reduction, indicating a significant therapeutic benefit.

While this accelerated approval is a pivotal milestone, additional data will be required to further confirm the long-term efficacy and safety of this therapy.

Eventos Adversos y Advertencias

Common adverse events reported in more than 10% of patients treated with pariglasgene brecaparvovec include elevated liver enzymes (71%), nausea (38%), and headaches (24%), among others. The labeling for this drug also carries warnings regarding hypersensitivity, hepatotoxicity, and contraindications for certain conditions such as severe hepatic fibrosis.

It is important to note that this therapy should not be administered during pregnancy, and careful consideration is required for patients with existing liver conditions.

Nota de Descargo de Responsabilidad

La información presentada en este documento es únicamente con fines informativos. Cualquier tratamiento debe ser discutido y aprobado por un profesional de la salud.

Fuente: https://www.medpagetoday.com/genetics/generalgenetics/122697